Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Metabolic Disorder Therapeutics Market

Metabolic Disorder Therapeutics Market Trends

Report ID: GMI9801
Published Date: Jun 2024
Report Format: PDF

Download Free Sample

Metabolic Disorder Therapeutics Market Trends

Rising prevalence of metabolic disorders is a primary driver of the market.
For instance, the global rise in obesity rates directly correlates with higher incidences of type 2 diabetes and cardiovascular diseases. Additionally, genetic predispositions play a significant role in the development of certain metabolic disorders, highlighting the need for effective therapeutic interventions.
As the number of individuals affected by these conditions grows, the demand for treatments and management strategies increases, thereby expanding the market for metabolic disorder therapeutics.
Further, increased awareness and early detection of metabolic disorders, driven by government initiatives and public health programs, are significantly boosting the demand for therapeutics. Early diagnosis and timely interventions improve patient outcomes and reduce long-term healthcare costs, thereby contributing to market growth.

Authors: Mariam Faizullabhoy , Gauri Wani

Frequently Asked Questions (FAQ) :

Metabolic disorder therapeutics industry size was USD 74.4 billion in 2023 and will grow at 7.5% CAGR between 2024 and 2032 due to rising prevalence of metabolic disorders, such as diabetes, obesity, and thyroid disorders worldwide.

The hospitals segment in the market will record USD 74.2 billion by 2032, driven by its pivotal role as a primary healthcare provider for patients with complex metabolic conditions.

North America metabolic disorder therapeutics industry will expand at 7.2% CAGR through 2032, attributed to high prevalence rates of conditions like diabetes and obesity, coupled with the sophisticated healthcare infrastructure.

Amgen Inc., AstraZeneca plc, Biocon Ltd., BioMarin Pharmaceutical, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla, Inc., CymaBay Therapeutics, Inc., Eli Lilly and Company, Merck KGaA, Novo Nordisk A/S, and Sanofi SA, among others.